Anthem Biosciences Q2 Results FY27 Preview: Results Date, Expectations and the Numbers That Will Decide the September 2026 Quarter
- September 9, 2026
- Posted by: Harsh Piplani
- Category: Results
Anthem Biosciences share price Rs 959.85 on 9 September 2026, up 0.21%. Q2 FY27 results date not confirmed. Q1 FY27 net profit Rs 120.00 crore. Q2 FY26 base a profit of Rs 173.00 crore.
Quick Answer
The Anthem Biosciences Q2 results date for FY27 is not confirmed, and Anthem Biosciences Ltd. had not filed a board meeting intimation with the NSE or BSE as of 9 September 2026. Indian listing rules require the September 2026 quarter results to be published within 45 days of the quarter end, an outer deadline of 14 November 2026. The quarter will be measured against a September 2025 base of Rs 550.00 crore in revenue and a profit of Rs 173.00 crore. This preview uses reported actuals only and carries no estimated revenue or profit figure for the coming quarter.
The Anthem Biosciences Q2 results FY27 announcement is the next scheduled earnings event for Anthem Biosciences Ltd., a contract research, development and manufacturing organisation serving pharmaceutical and biotechnology customers, alongside a specialty ingredients business. The stock traded at Rs 959.85 on the NSE on 9 September 2026, up 0.21% from the previous close of Rs 957.80, about 1.4% below its 52-week high of Rs 973.50 and 65.7% above its 52-week low of Rs 579.15.
What makes the Anthem Biosciences Q2 results print worth watching is the base it faces. The September 2025 quarter delivered Rs 550.00 crore of revenue and a profit of Rs 173.00 crore, while the most recent quarter on record, Q1 FY27, produced Rs 418.00 crore and a profit of Rs 120.00 crore. Everything below is built from those reported figures rather than from any forecast.
Click Here – Get Free Investment Predictions
When Is the Anthem Biosciences Q2 Results FY27 Date?
The Anthem Biosciences Q2 results date for FY27 is not confirmed. As of 9 September 2026, Anthem Biosciences Ltd. had not filed a board meeting intimation with the NSE or BSE for the September 2026 quarter, so any date circulating before that filing appears should be treated as unverified.
What can be stated is the regulatory boundary. Listed companies in India must publish quarterly results within 45 days of the end of the quarter, which places the outer deadline for the September 2026 quarter at 14 November 2026. Companies also have to give the exchanges prior intimation of the board meeting that approves the results, so the Anthem Biosciences Q2 results date becomes public through that filing rather than through any advance announcement.
The Anthem Biosciences Q2 results FY27 print covers 1 July 2026 to 30 September 2026. Small and mid-cap companies more often report in the second half of that window than in the first, so late October or early November is the range to watch for Anthem Biosciences.
Anthem Biosciences Q2 Results Expectations: What the Market Is Actually Tracking
No verified analyst estimate for the Anthem Biosciences Q2 results FY27 quarter is in the public domain, so no revenue or profit figure should be assumed for Anthem Biosciences. The Anthem Biosciences Q2 results watchlist below is built from what the company has actually reported and disclosed.
The first is the strength of the September 2025 base. That quarter delivered Rs 550 crore of revenue at a 40% operating margin and Rs 173 crore of profit, the second best of the five, so the comparison this year is against a demanding number.
The second is that revenue swings quarter to quarter, from Rs 418 crore to Rs 611 crore across the period. Contract manufacturing campaigns and milestone-linked research revenue do not spread evenly, so quarterly lumpiness is normal here.
The third is other income, which ran Rs 48 crore in September 2025 and Rs 52 crore in March 2026 against only Rs 8 crore in December. Part of the difference between the best and worst quarters sits in that line rather than in operations.
Check Anthem Biosciences Ltd. Live Fundamentals on the Univest Screener
Anthem Biosciences Q2 Results Preview: The Q1 FY27 Actuals It Builds On
Anthem Biosciences Ltd. reported revenue of Rs 418.00 crore in Q1 FY27, down 22.59% from Rs 540.00 crore in Q1 FY26, and a profit of Rs 120.00 crore at the net level, down 11.76% from Rs 136.00 crore in Q1 FY26. These are reported actuals, not estimates.
Sequentially, revenue was down 31.59% over the March 2026 quarter figure of Rs 611.00 crore, and net profit was down 36.84% from Rs 190.00 crore in Q4 FY26. Operating margin stood at 36% in Q1 FY27 against 40% in the September 2025 quarter, which is the comparison the Anthem Biosciences Q2 results print will be read against.
Q2 FY26 Base: The Comparison Anthem Biosciences Q2 Results FY27 Must Beat
Anthem Biosciences Ltd. reported revenue of Rs 550.00 crore and a profit of Rs 173.00 crore in Q2 FY26, the September 2025 quarter. That is the year-ago base against which the September 2026 numbers will be judged, and it is the single most useful figure in this Anthem Biosciences Q2 results preview.
Net profit in that base quarter was above the Rs 120.00 crore just reported for Q1 FY27, so the year-on-year comparison starts from a demanding level. Revenue of Rs 550.00 crore sits above the Rs 418.00 crore of the June 2026 quarter, which frames how much sequential movement the Anthem Biosciences Q2 results print needs to show growth.
Anthem Biosciences Quarterly Results Trend Over the Last Four Quarters
| Quarter | Revenue (Rs Cr) | Net Profit (Rs Cr) |
|---|---|---|
| Q2 FY26 (Sep 2025) | 550.00 | 173.00 |
| Q3 FY26 (Dec 2025) | 423.00 | 93.00 |
| Q4 FY26 (Mar 2026) | 611.00 | 190.00 |
| Q1 FY27 (Jun 2026) | 418.00 | 120.00 |
Figures in brackets denote negative numbers. All four quarters above are reported actuals taken from the company’s exchange filings, and they are the only basis this Anthem Biosciences Q2 results preview uses.
Revenue across those four quarters ranged from Rs 418.00 crore to Rs 611.00 crore, and net profit from Rs 93.00 crore to Rs 190.00 crore. That spread is the honest context for the Anthem Biosciences Q2 results FY27 print, and it is why a single quarter should not be read as a trend on its own.
Key Factors That Could Shape Anthem Biosciences Q2 Results FY27
The Anthem Biosciences Q2 results outcome will turn on a small number of company-specific variables rather than on broad market conditions. The three below are the ones visible in what Anthem Biosciences has already reported.
Campaign Timing in the Manufacturing Book
Commercial manufacturing runs in campaigns scheduled with customers, so a quarter can carry two large batches or none. The June 2026 revenue of Rs 418 crore against Rs 611 crore in March is that scheduling rather than lost business.
Customer Pipeline Progression
Research and development revenue depends on how many customer molecules advance through the stages, and each advance raises the value of the work. The disclosed order position matters more than any single quarter’s revenue.
High Multiple on a Short Listed Record
The stock trades at a price-to-earnings ratio of 91.08 and 17.71 times a book value of Rs 54.20, on a return on equity of 22.30%. It listed in July 2025, so the reported record as a listed company covers about five quarters.
Anthem Biosciences Q2 Results FY27: Share Price and Valuation Going Into the Print
Anthem Biosciences share price today is Rs 959.85 on the NSE, up Rs 2.05 or 0.21% from the previous close of Rs 957.80 on 9 September 2026, ahead of the Anthem Biosciences Q2 results announcement.
| Metric | Value (9 September 2026) |
|---|---|
| NSE Symbol | ANTHEM |
| Current Market Price | Rs 959.85 |
| 52-Week High | Rs 973.50 |
| 52-Week Low | Rs 579.15 |
| Market Capitalisation | Rs 54,061 crore |
| PE Ratio | 91.08 |
| PB Ratio | 17.71 |
| EPS (TTM) | Rs 10.54 |
| Book Value per Share | Rs 54.20 |
| Debt to Equity | 0.02 |
| Return on Equity | 22.30% |
| 50-Day Moving Average | Rs 838.62 |
| 200-Day Moving Average | Rs 730.65 |
| RSI (14) | 70.66 |
The stock trades above both its 50-day average of Rs 838.62 and its 200-day average of Rs 730.65, with a 14-day RSI of 70.66. None of this is a view on where the shares go once the Anthem Biosciences Q2 results are announced, and no price target is offered here.
Download the Univest iOS App or Univest Android App to track Anthem Biosciences Ltd. live price and quarterly earnings updates.
What Investors Should Watch When Anthem Biosciences Q2 Results Are Announced
Four lines carry most of the information in a company of this size, and reading them in order keeps the Anthem Biosciences Q2 results print in proportion.
- Revenue against the Rs 550.00 crore reported in the September 2025 base quarter
- Net profit against a profit of Rs 173.00 crore in that same quarter
- Operating margin against 36% in Q1 FY27
- Any exceptional item, provision or one-off gain disclosed alongside the numbers
A one-off gain or provision can move the reported profit far more than operations do in a company this size, which is why the Anthem Biosciences Q2 results announcement should be read together with the notes to the results rather than the headline alone.
Conclusion on Anthem Biosciences Q2 Results FY27
The Anthem Biosciences Q2 results date is not confirmed, and 14 November 2026 is the statutory outer limit rather than an expected date. Anthem Biosciences Ltd. will make the schedule public through a board meeting intimation to the exchanges, and until then the September 2026 quarter can only be framed by what has already been reported.
On that basis the Anthem Biosciences Q2 results FY27 print faces a base of Rs 550.00 crore in revenue and a profit of Rs 173.00 crore, with the most recent quarter having delivered Rs 418.00 crore and a profit of Rs 120.00 crore. No numerical estimate appears in this preview because no verified consensus figure exists for Anthem Biosciences, and readers should treat any preview that supplies one with caution. Verify every figure against the company filing on release and consult a SEBI-registered advisor before acting on quarterly earnings.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
FAQs on Anthem Biosciences Q2 Results FY27
What is the Anthem Biosciences Q2 results date for FY27?
Ans. The Anthem Biosciences Q2 results date for FY27 is not confirmed. Anthem Biosciences Ltd. had not filed a board meeting intimation with the NSE or BSE as of 9 September 2026. Indian listing rules require the September 2026 quarter results to be published by 14 November 2026 at the latest.
What quarter do the Anthem Biosciences Q2 results 2026 cover?
Ans. The Anthem Biosciences Q2 results FY27 cover 1 July 2026 to 30 September 2026, known as the September 2026 quarter. Anthem Biosciences Ltd. reports revenue, operating profit and net profit for that period, and the Anthem Biosciences Q2 results filing also carries the notes to the accounts.
What were the Anthem Biosciences Q1 FY27 results?
Ans. Anthem Biosciences Ltd. reported revenue of Rs 418.00 crore in Q1 FY27 and a profit of Rs 120.00 crore at the net level. Revenue was down 22.59% versus Q1 FY26 and net profit was down 11.76% from Rs 136.00 crore in Q1 FY26.
What were Anthem Biosciences Q2 FY26 results in the September 2025 quarter?
Ans. Anthem Biosciences Ltd. reported revenue of Rs 550.00 crore and a profit of Rs 173.00 crore in Q2 FY26. Operating margin was 40%. Those figures form the base for the Anthem Biosciences Q2 results FY27 comparison.
What are the main Anthem Biosciences Q2 results expectations this quarter?
Ans. No verified analyst estimate is publicly available. The Anthem Biosciences Q2 results expectations centre on revenue against the Rs 550.00 crore base, net profit against a profit of Rs 173.00 crore, operating margin against 36% in Q1 FY27, and any exceptional item disclosed with the numbers.
What is Anthem Biosciences share price today ahead of the Q2 earnings?
Ans. Anthem Biosciences share price is Rs 959.85 on the NSE as of 9 September 2026, up 0.21% from Rs 957.80. The stock is about 1.4% below its 52-week high of Rs 973.50 and 65.7% above its 52-week low of Rs 579.15, at a market capitalisation of Rs 54,061 crore.
Is Anthem Biosciences a good stock to buy before the Q2 results?
Ans. This article does not offer a buy, sell or hold recommendation on Anthem Biosciences Ltd.. The stock trades at a price-to-book ratio of 17.71 with a return on equity of 22.30%. Assess the reported numbers when they are released and consult a SEBI-registered financial advisor before making any decision.
